MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Neurocrine Biosciences Inc

Fermé

SecteurSoins de santé

102.61 -5.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

102.27

Max

107.9

Chiffres clés

By Trading Economics

Revenu

-27M

103M

Ventes

5.6M

628M

P/E

Moyenne du Secteur

33.617

63.778

BPA

1.69

Marge bénéficiaire

16.425

Employés

1,800

EBITDA

-39M

152M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+53.74% upside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3.8B

11B

Ouverture précédente

107.86

Clôture précédente

102.61

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Neurocrine Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 janv. 2025, 00:03 UTC

Actions en Tendance

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 mars 2025, 09:30 UTC

Actualités

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13 août 2024, 11:30 UTC

Actualités

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Comparaison

Variation de prix

Neurocrine Biosciences Inc prévision

Objectif de Prix

By TipRanks

53.74% hausse

Prévisions sur 12 Mois

Moyen 164.5 USD  53.74%

Haut 192 USD

Bas 138 USD

Basé sur 22 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

22 ratings

17

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

106.49 / 110.685Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.